Your browser doesn't support javascript.
loading
Transfusion-associated adverse events and implementation of blood safety measures - findings from the 2017 National Blood Collection and Utilization Survey.
Savinkina, Alexandra A; Haass, Kathryn A; Sapiano, Mathew R P; Henry, Richard A; Berger, James J; Basavaraju, Sridhar V; Jones, Jefferson M.
Afiliación
  • Savinkina AA; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Haass KA; Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee.
  • Sapiano MRP; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Henry RA; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Berger JJ; Office of HIV/AIDS and Infectious Disease Policy, Office of the Assistant Secretary for Health, U.S. Department of Health and Human Services, Washington, District of Columbia.
  • Basavaraju SV; Office of HIV/AIDS and Infectious Disease Policy, Office of the Assistant Secretary for Health, U.S. Department of Health and Human Services, Washington, District of Columbia.
  • Jones JM; Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Transfusion ; 60 Suppl 2: S10-S16, 2020 03.
Article en En | MEDLINE | ID: mdl-32134123
BACKGROUND: Serious transfusion-associated adverse events are rare in the United States. To enhance blood safety, various measures have been developed. With use of data from the 2017 National Blood Collection and Utilization Survey (NBCUS), we describe the rate of transfusion-associated adverse events and the implementation of specific blood safety measures. STUDY DESIGN AND METHODS: Data from the 2017 NBCUS were used with comparison to already published estimates from 2015. Survey weighting and imputation were used to obtain national estimates of transfusion-associated adverse events, and the number of units treated with pathogen reduction technology (PRT), screened for Babesia, and leukoreduced. RESULTS: The rate of transfusion-associated adverse events requiring any diagnostic or therapeutic interventions was stable (275 reactions per 100,000 transfusions in 2015 and 282 reactions per 100,000 transfusions in 2017). In 2017 among US blood collection centers, 16 of 141 (11.3%) reported screening units for Babesia and 28 of 144 (19.4%) reported PRT implementation; 138 of 2279 (6.1%) hospitals reported transfusing PRT-treated platelets. In 2017, 134 of 2336 (5.7%) hospitals reported performing secondary bacterial testing of platelets (50,922 culture-based and 63,220 rapid immunoassay tests); in 2015, 71 of 1877 (3.8%) hospitals performed secondary testing (87,155 culture-based and 21,779 rapid immunoassay tests). Nearly all whole blood/red blood cell units and platelet units were leukoreduced. CONCLUSIONS: Besides leukoreduction, implementation of most blood safety measures reported in this study remains low. Nationally, hospitals might be shifting from culture-based secondary bacterial testing to rapid immunoassays.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Seguridad de la Sangre / Reacción a la Transfusión Tipo de estudio: Diagnostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Transfusion Año: 2020 Tipo del documento: Article País de afiliación: Georgia Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Seguridad de la Sangre / Reacción a la Transfusión Tipo de estudio: Diagnostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Transfusion Año: 2020 Tipo del documento: Article País de afiliación: Georgia Pais de publicación: Estados Unidos